Last updated: April 24, 2026
Who Supplies Bosentan API and Finished Dosage?
Bosentan (trade name: Tracleer) is supplied globally through a mix of originator-licensed branded manufacturers and generic API and finished-dose suppliers. For procurement and IP-risk screening, the key is to separate bosentan API (active pharmaceutical ingredient) suppliers from finished tablets (film-coated) manufacturers, since the supply chain differs by jurisdiction and tender requirements.
What products and supply categories exist for bosentan?
Bosentan is marketed as an oral solid dose (tablets) and is manufactured using bosentan as the active pharmaceutical ingredient. Two supply layers dominate commercial sourcing:
-
Bosentan API manufacturers
- Sell bosentan substance to formulators and contract manufacturers.
- Supply chain documentation typically includes DMF/ASMF, CEP, GMP compliance, and batch release history.
-
Finished-dose manufacturers (tablets)
- Produce the marketed product form (typically film-coated tablets).
- Source API from qualifying vendors and run finished-dose GMP at a drug-product site.
The commercial landscape is best understood by named market authorizations (brands and generics) and their API sourcing/DMF linkage, rather than by a single “bosentan supplier” label.
Which firms have marketed bosentan tablets?
The marketed bosentan portfolio is anchored by the originator brand and then expanded via generics. The originator and major generics define the easiest path to identify manufacturing sites and procurement routes.
Originator
- Tracleer (bosentan): Actelion Pharmaceuticals (Janssen/Johnson & Johnson corporate successor structure)
Representative generic brands and likely supply routes
Generic bosentan tablets are marketed under multiple trade names across the EU, UK, and other regions. The practical procurement approach is to map each local marketing authorization to:
- the finished-dose MAH (marketing authorization holder)
- the manufacturing site(s) listed on the product’s label/SmPC
- the API DMF/CEP referenced for the strength and dosage form
This is where suppliers become verifiable and auditable for sourcing decisions.
Which companies supply bosentan API?
Bosentan API supply is typically handled by a small set of large chemical and API manufacturers plus regional specialists. In practice, buyers identify API sources by triangulating:
- DMF/ASMF holders linked to specific bosentan strengths
- CEP holders (where applicable)
- GMP inspection scope for bosentan
- technical agreements used by finished-dose manufacturers
The “supplier list” for bosentan API changes over time as DMFs are filed, updated, and withdrawn, and as dossiers are cross-referenced by generics in each market.
How should buyers screen bosentan suppliers (procurement criteria)?
Bosentan procurement should be filtered on documentation and quality systems, not on marketing claims. For both API and finished doses, the minimum screening set is:
- Regulatory status
- API: whether the company holds a DMF/ASMF entry relevant to bosentan and referenced by approved products
- Finished dose: whether manufacturing sites appear in product dossiers for the target region
- GMP compliance
- Manufacturing site inspection status aligned to EU/US/ICH expectations
- Supply continuity
- Ability to provide batch documentation, impurity profile control strategy, and stability data package
- Technical package readiness
- CoA format, specification sheet, method summaries, and change-control history
- Commercial fit
- Lead time, MOQ, Incoterms, and packaging format for the destination market
What are the practical supplier “shortlists” for bosentan?
Because bosentan is well established and off-patent in many jurisdictions, most procurement shortlists include:
- 1 to 3 API vendors that can supply consistently with complete documentation
- 2 to 5 finished-dose manufacturers that can produce tablets at the required strengths and packaging formats
A robust shortlist is built market-by-market using the product dossiers and then validated through:
- technical assessment (specifications and impurity profile)
- quality agreement
- regulatory inspection outcomes where available
Key Takeaways
- Bosentan sourcing splits into API suppliers and finished-dose manufacturers, with different qualification paths.
- The most reliable way to identify concrete suppliers is via marketing authorization dossiers (finished doses) and DMF/ASMF/CEP references (API).
- For procurement, the critical differentiator is not “who sells bosentan,” but which suppliers are referenced by approved products in the target jurisdiction and meet GMP and documentation readiness.
FAQs
-
Is bosentan API sourced through the originator or multiple vendors?
It is sourced through a multi-vendor supply chain. Finished-dose manufacturers typically qualify multiple API sources via referenced dossiers.
-
Do bosentan tablets require different supplier qualification than bosentan API?
Yes. Tablets require finished-dose GMP and finished product release testing, even if the API is qualified.
-
What is the best method to confirm an API supplier for bosentan?
Confirm via DMF/ASMF/CEP references tied to approved finished-dose products in the target market.
-
What documentation matters most for bosentan procurement?
DMF/ASMF or CEP linkage, GMP status, CoA/specifications, impurity profile controls, and stability/validation package.
-
How fast does the bosentan supplier landscape change?
It changes as dossiers are updated and sites gain or lose qualification. Market authorization mapping is the most stable verification approach.
References
[1] EMA. Tracleer (bosentan) EPAR and product information (SmPC). European Medicines Agency.
[2] FDA. Drug Approval Reports / Labeling for Tracleer (bosentan). U.S. Food and Drug Administration.
[3] European Commission. Community Register of GMP certificates (where applicable) and dossier-linked manufacturing site information via national databases. European Commission.
